Short Interest in Finch Therapeutics Group, Inc. (NASDAQ:FNCH) Increases By 383.3%

Finch Therapeutics Group, Inc. (NASDAQ:FNCH) was the recipient of a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 11,600 shares, an increase of 383.3% from the February 29th total of 2,400 shares. Based on an average daily trading volume, of 19,000 shares, the days-to-cover ratio is presently 0.6 days. Approximately 2.2% of the company’s shares are sold short.

Finch Therapeutics Group Price Performance

Shares of NASDAQ FNCH opened at $2.84 on Thursday. Finch Therapeutics Group has a 52-week low of $2.19 and a 52-week high of $16.74. The business’s 50 day moving average is $2.66 and its two-hundred day moving average is $3.61.

Finch Therapeutics Group (NASDAQ:FNCH) last issued its earnings results on Monday, March 25th. The company reported ($1.89) EPS for the quarter.

Hedge Funds Weigh In On Finch Therapeutics Group

A number of institutional investors and hedge funds have recently modified their holdings of the company. MSD Partners L.P. acquired a new stake in shares of Finch Therapeutics Group during the third quarter worth about $26,000. BlackRock Inc. raised its holdings in Finch Therapeutics Group by 2.3% during the first quarter. BlackRock Inc. now owns 404,931 shares of the company’s stock worth $2,038,000 after purchasing an additional 9,149 shares in the last quarter. Millennium Management LLC purchased a new position in Finch Therapeutics Group in the second quarter valued at about $259,000. Renaissance Technologies LLC increased its holdings in Finch Therapeutics Group by 19.4% in the first quarter. Renaissance Technologies LLC now owns 45,000 shares of the company’s stock valued at $226,000 after buying an additional 7,314 shares in the last quarter. Finally, Vanguard Group Inc. increased its holdings in Finch Therapeutics Group by 10.0% in the third quarter. Vanguard Group Inc. now owns 35,939 shares of the company’s stock valued at $186,000 after buying an additional 3,263 shares in the last quarter. Institutional investors and hedge funds own 21.77% of the company’s stock.

Finch Therapeutics Group Company Profile

Finch Therapeutics Group, Inc, a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease.